Flyer

Annals of Clinical and Laboratory Research

  • ISSN: 2386-5180
  • Journal h-index: 16
  • Journal CiteScore: 5.60
  • Journal Impact Factor: 4.86
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
+44 7460731551
Awards Nomination
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
Share This Page

Abstract

Convalescent Plasma Therapy for Prophylaxis and Treatment of COVID-19: A Systematic Research of Facts and Files, A Narrative Review

Koduri Sridevi, Amit Munjal, Ajay Chandran, Nachiappan S,Praveena Raman, Sukriti Bhalla, Sourya Kumar, Abhishek Singh Nayyar

Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same.